RVNC News and Press, Revance Therapeutics Inc. From 05/02/23

Conference Call Scheduled for Tuesday, May 9, 2023 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding conference ...

Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that the company will participate in the 22 nd Annual Needham Virtual Healthcare Conference, taking place April 17 – 20, 2023. Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday,...

2023-04-03 19:57:20 ET Summary Today, we take a deeper look at Revance Therapeutics, Inc., a developer of aesthetic products that is seeing rapid revenue growth. The company has potential catalysts on the horizon but is bumping up against analyst price targets and has a high cash ...

Revance Therapeutics, Inc. (RVNC), today announced the release of its 2022 ESG Report, detailing the company’s progress towards its ESG priorities of innovation and access, workplace culture and strong corporate governance. The report was guided by the Sustainability Accounting Standards...

2023-03-09 11:57:15 ET The following slide deck was published by Revance Therapeutics, Inc. in conjunction with this event. For further details see: Revance Therapeutics (RVNC) Investor Presentation _ Slodeshow

Revance Therapeutics, Inc. (RVNC) Q4 2022 Earnings Conference Call February 28, 2023 4:30 AM ET Company Participants Jessica Serra – Head of Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke &...

Revance Therapeutics press release ( NASDAQ: RVNC ): Q4 GAAP EPS of -$1.82 misses by $0.78 . Revenue of $49.9M (+92.3% Y/Y) beats by $4.8M . Sales primarily increased due to sales of the RHA Collection and sales of DAXXIFY® during the PrevU program. DAXXI...

Q4 and full year 2022 total revenue of $49.9 million and $132.6 million, a YoY increase of 92% and 70%, respectively. Q4 and full year 2022 RHA® Collection revenue of $34.8 million and $107.2 million, a YoY increase of 46% and 51%, respectively. DAXXIFY® Q4 PrevU revenue of $11....

- Dr. Coric currently serves as the Chairman and Chief Executive Officer of Biohaven (BHVN) - Revance Therapeutics, Inc . (RVNC), announced today the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023. Dr. Coric brings more than 22 years of drug de...

Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the 43 rd Annual Cowen Healthcare Conference, taking place March 6-8, 2023, in Boston, Massachusetts. President, Dustin S. Sjuts, and Chief Financial Officer, Tobin Schilke, are scheduled to participat...